These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban.
    Author: Fawole A, Daw HA, Crowther MA.
    Journal: Cleve Clin J Med; 2013 Jul; 80(7):443-51. PubMed ID: 23821689.
    Abstract:
    The new oral anticoagulants dabigatran etexilate (Pradaxa), rivaroxaban (Xarelto), and apixaban (Eliquis) have predictable pharmacokinetic and pharmacodynamic profiles and are alternatives to warfarin. However, many physicians are wary of these drugs, since there is limited evidence on how to manage bleeding in patients taking them, and since no specific antidote is known to reverse their anticoagulant effect. Management requires careful adherence to first principles of bleeding care. Unapproved and untested reversal strategies may be required in patients with life-threatening bleeding.
    [Abstract] [Full Text] [Related] [New Search]